| Literature DB >> 28740442 |
Rajendra Chaudhary1, Anju Dubey2, Atul Sonker3.
Abstract
Blood donor hemoglobin (Hb) estimation is an important donation test that is performed prior to blood donation. It serves the dual purpose of protecting the donors' health against anemia and ensuring good quality of blood components, which has an implication on recipients' health. Diverse cutoff criteria have been defined world over depending on population characteristics; however, no testing methodology and sample requirement have been specified for Hb screening. Besides the technique, there are several physiological and methodological factors that affect accuracy and reliability of Hb estimation. These include the anatomical source of blood sample, posture of the donor, timing of sample and several other biological factors. Qualitative copper sulfate gravimetric method has been the archaic time-tested method that is still used in resource-constrained settings. Portable hemoglobinometers are modern quantitative devices that have been further modified to reagent-free cuvettes. Furthermore, noninvasive spectrophotometry was introduced, mitigating pain to blood donor and eliminating risk of infection. Notwithstanding a tremendous evolution in terms of ease of operation, accuracy, mobility, rapidity and cost, a component of inherent variability persists, which may partly be attributed to pre-analytical variables. Hence, blood centers should pay due attention to validation of test methodology, competency of operating staff and regular proficiency testing of the outputs. In this article, we have reviewed various regulatory guidelines, described the variables that affect the measurements and compared the validated technologies for Hb screening of blood donors along with enumeration of their merits and limitations.Entities:
Keywords: blood donors; copper sulfate method; cut off criteria; hemoglobin estimation; noninvasive spectrophotometry; portable hemoglobinometers; pre-analytical variables
Year: 2017 PMID: 28740442 PMCID: PMC5503668 DOI: 10.2147/JBM.S103788
Source DB: PubMed Journal: J Blood Med ISSN: 1179-2736
Hb screening criteria in various guidelines
| S. No. | Guidelines | Criterion |
|---|---|---|
| 1 | US FDA | Cutoff is 12.5 g/dL of Hb for both male and female donors |
| 2 | AABB | Requires an hct equivalent of 38%. Ear lobe capillary sample has been stated to be unacceptable for the purpose of allogenic or autologous blood donation |
| 3 | UK Blood Transfusion Guidelines | Minimum Hb level of 12.5 g/dL for females and 13.5 g/dL for males, translating into hct levels of 38% and 40%, respectively |
| 4 | EU Blood Transfusion Guidelines | Hb level of ≥12.5 g⁄dL for females and ≥13.5 g⁄dL for males |
| 5 | Japanese Red Cross Society | Cutoff has been set at 12 and 12.5 g/dL, for 200 and 400 mL donations, respectively, for females and 12.5 and 13 g/dL, for 200 and 400 mL donations, respectively, for males |
| 6 | Brazilian guidelines | The minimum acceptable value of Hb for blood donation is 12.5 g/dL for females and 13.0 g/dL for males |
| 7 | Drugs and Cosmetics Act India | Both males and females should have at least 12.5 g/dL of Hb or 38% hct |
Abbreviations: Hb, hemoglobin; FDA, Food and Drug Administration; AABB, American Association of Blood Banks; hct, hematocrit; EU, European Union.
Measures of performance of Hb screening tests
| S. No. | Measure | Description |
|---|---|---|
| 1 | Sensitivity | It is the percentage of donors with an Hb value below the cutoff (failed) identified by the test out of all venous Hb values below the cutoff. It denotes the ability of the test to prevent donation from anemic donors |
| 2 | Specificity | It is the percentage of donors recruited for blood donation (passed) by the test out of all with venous Hb above the cutoff value |
| 3 | Positive predictive value | It is the probability that a below-cutoff value on the test method be actually lower than a cutoff value by the reference method |
| 4 | Negative predictive value | It is the probability of an above-cutoff value to be actually so by the reference method, important for donor safety |
| 5 | Accuracy | It is the degree of agreement of the measurements obtained by a test method with the reference value. It is calculated as the ratio of donors categorized correctly (accepted or deferred appropriately) to all donors tested |
| 6 | Precision | It is the closeness of agreement among a set of results. If a test method is precise, results may be reliably reproduced and the amount of random variation is small |
| 7 | CV | It is a measure of dispersion that describes the amount of variability relative to a mean value, calculated as a ratio of SD to mean. It is critical in determining if an assay can determine the Hb values with confidence |
Abbreviations: Hb, hemoglobin; CV, coefficient of variation; SD, standard deviation.
Studies comparing Hb and hct levels in blood obtained from various anatomical sites
| S. No. | Authors | Parameter | Method | Mean value (±SD) of ELS | Mean value (±SD) of FS | Mean value (±SD) of VS | Inference |
|---|---|---|---|---|---|---|---|
| 1 | Avoy et al | hct (%) | Microhematocrit | 46.84±4.24 (male) | 44.14±3.20 (male) | 42.26±2.60 (male) | Statistically significant difference in ELS, FS and VS ( |
| 2 | Coburn et al | hct (%) | Microhematocrit | 47.820±3.978 | 40.640±3.141 | 40.860±2.680 | ELS hct significantly higher than FS and VS ( |
| 3 | Pi et al | Hb (g/dL) | FS by Hemocue, VS by automated hematology analyzer | – | 13.5±1.02 | 13.26±0.72 | FS capillary sample has 0.32 g/dL higher Hb level |
| 4 | Wood et al | hct (%) | Microhematocrit | 47.3±4.2 | 42.7±2.8 | 42.5±3.1 | Hct determinations from ELS samples |
| 5 | Radtke et al | Hb (g/dL) | ELS and FS by PH, VS by hematology analyzer | 15.96±1.57 (male) | 14.99±1.28 (male) | 14.59±1.15 (male) | Mean overestimation with ear-stick sample was 7.8% |
| 6 | Darragh et al | Hb (g/dL) | FS by Hemocue, VS by hematology analyzer | – | 13.1±0.2 (male) | 14.1±0.7 (male) | A cutoff for capillary Hb of 12 g/dL for females and 13 g/dL for males equates to venous Hb that meets regulatory requirements:12.5 and 13.5 g/dL, respectively |
| 7 | Schalk et al | Hb (mmol/L) | Hematology analyzer Advia 120 | – | 8.2±1.5 | 8.0±1.5 | Mean differences between capillary and venous hematological values of +1.8% |
| 8 | Zeimann et al | Hb (g/dL) | FS by Hemocue, VS by hematology analyzer | – | 15.59±1.08 (male) | 15.38±0.87 (male) | Mean deviation 0.54 g/dL |
| 9 | Rudolf-Oliveira et al | Hb (g/dL) | Hemocue | – | 14.8±1.5 | 14.4±1.4 | Capillary Hb higher than venous |
| 10 | Patel et al | Hb (g/dL) | Hemocue 201 | – | 14.05±1.51 | 13.89±1.31 | Capillary Hb levels were found to be significantly higher than venous Hb levels |
| 11 | Singh et al | Hb (g/dL) | HemoControl | – | 14.32±1.41 | 14.40±1.54 | Differences not statistically significant ( |
Abbreviations: Hb, hemoglobin; hct, hematocrit; SD, standard deviation; ELS, ear lobe sample; FS: finger-stick sample; VS, venous sample.
Evaluation of performance of PH for blood donor Hb screening
| S. No. | Author | Reference method (automated hematology analyzer) | PH | Bias | Accuracy | Performance characteristics | Precision | Inference |
|---|---|---|---|---|---|---|---|---|
| 1 | Tondon et al | ABX Micros 60 | HemoCue | +0.24 g/dL | 97% | Sensitivity 99.4%, specificity 84.4%, PPV 97% and NPV 96.6% | – | Bias nonsignificant. Recommended for subsequent testing of inappropriate deferrals by CuSO4 |
| 2 | Mendrone et al | ABX Pentra 60 | HemoCue 201 | +0.77 g/dL | 89.3% | Sensitivity 56% and specificity 93.5% | – | HemoCue 201+ showed greater discriminating power for detecting anemia in prospective blood donors than the micro-hct method |
| 3 | Sawant et al | Beckman Coulter Counter | HemoCue | +1.5 g/dL | – | Sensitivity 99%, specificity 45%, PPV 43% and NPV 99% | – | Concordance correlation coefficient between HemoCue and the reference method (0.74) |
| 4 | Gómez-Simón et al | Coulter MAXM | HemoCue | +0.78±0.73 g/dL | 82% | CV 2.28±0.73% | HemoCue showed the best agreement with venous Hb determination | |
| STAT-Site M Hgb | +0.51±0.96 g/dL | 76% | – | CV 4.79±1.74% | ||||
| CompoLab Hb | No significant difference | 85% | – | CV 3.74±2.21% | ||||
| 5 | Rudolf-Oliveira et al | Sysmex XE-2100D | HemoCue | +0.72 g/dL | ICC 0.763 | – | – | Repeat on automated hematology analyzer with venous blood when capillary Hb level is near borderline |
| 6 | Patel et al | Cell-Dyn 4000 | HemoCue 201 | +0.69 g/dL | 90.6% | – | Mean absolute difference in duplicate tests of 0.76 (relative error 5.6%) | Hb with HemoCue consistently higher than the reference method |
| 7 | Kim et al | Beckman Coulter LH500 | HemoCue | +0.3 g/dL | ICC 0.86 | Sensitivity 42.7% and specificity 98.6% | – | Hb measurements by HemoCue showed excellent agreement with the automated hematology analyzer |
| 8 | Belardinelli et al | Beckman Coulter | HemoCue | +0.83±0.70 g/dL | 92% | Sensitivity 99% and specificity 99.5% | – | Higher accuracy than NIS devices |
| 9 | Shahshahani and Amiri | Roche ABX Cobas Micros | HemoCue 201 | +0.79 g/dL | For Hb<12.5 g/dL, 97.5% | For Hb<12.5 g/dL, sensitivity 79.5%, specificity 100%, PPV 100% and NPV 97.2% | – | Qualitative methods to be used for primary screening, and accurate quantitative methods to be used in clinically suspicious cases or when qualitative methods fail |
| 10 | Singh et al | Sysmex KX-21 | DiaSpect | −0.18 g/dL | For Hb>18 g/dL, 81.5% | For Hb>18 g/dL, sensitivity 100%, specificity 79.8%, PPV 31.7% and NPV 100% | ||
| HemoControl | −0.22 g/dL | ICC 0.78 | Sensitivity 98.1%, specificity 78.4%, PPV 35.9% and NPV 99.7% | CV 2.19% | DiaSpect more accurate and rapid, therefore apt for donor screening | |||
| 11 | Baart et al | XT-188i, Sysmex | HemoCue 201 | Males | ICC 0.77 | Sensitivity 86.8%, specificity 94.7%, PPV 66.9% and NPV 98.3% | CV 2.51% | |
| Females | 94.1% | Sensitivity 30.1%, specificity 99.8%, PPV 94.4% and NPV 94.1% | – | Measurements with invasive devices showed strong correlation and better agreement with venous values | ||||
| HemoCue 301 | Males | 90% | Sensitivity 36.6%, specificity 98.9%, PPV 84.2% and NPV 90.3% | |||||
| Females | 93.7% | Sensitivity 27.9%, specificity 99.4%, PPV 79.2% and NPV 94.1% | ||||||
| 12 | Sümnig et al | Siemens Advia 2120i | HemoCue 301 | +0.43 g/dL | 87.7% | Sensitivity 27.9%, specificity 97.7%, PPV 67.4% and NPV 89% | ||
| 13 | Pagliaro et al | Beckman Coulter | HemoControl | – | 97.6% | Sensitivity 23.1%, specificity 99.2%, PPV 78.9% and NPV 90.6% | CV 3.23% | May be used as the second-line method to noninvasive devices in cases where retesting is required |
| 14 | Ardin et al | Sysmex KX 21n | CompoLab Hb | −0.53±0.81 g/dL | – | Males: sensitivity 13.22%, specificity 99.89%, PPV 88.46% and NPV 94.58% | – | Measuring Hb alone on PH not satisfactory |
| 92% | – | – | 4.48% prospective blood donors would falsely be deferred in using CompoLab Hb |
Note:
Statistically significant difference between PH and the reference Hb value (p<0.05). Data presented as mean ± standard deviation.
Abbreviations: PH, portable hemoglobinometer; Hb, hemoglobin; hct, hematocrit; CV, coefficient of variation; NIS, noninvasive spectrophotometry; PPV, positive predictive value; NPV, negative predictive value; ICC, intraclass correlation coefficient.
Evaluation of performance of NIS for blood donor screening
| S. No. | Author | Reference method (automated hematology analyzer) | NIS device | Bias | Accuracy | Performance characteristics | Inference |
|---|---|---|---|---|---|---|---|
| 1 | Kim et al | LH500 Beckman Coulter | NBM 200 | +0.1 g/dL | ICC 0.69 | Sensitivity 38.6% and specificity 93.6% | Application for donor screening requires further evaluation of technique |
| 2 | Pinto et al | Cell-Dyn Ruby, Abbott Laboratories | NBM 200 | +0.2 g/dL | Median of percentage errors was below the reference method | – | Good method in terms of precision and feasibility for anemia screening of blood donors |
| 3 | Weinstein et al | Coulter LH-750 | NBM 200 | +0.1 g/dL | Mean absolute error 0.85 g/dL, and the SD of error 1.02 g/dL | Sensitivity 82% Specificity 88% | Hb measurements by NBM 200 were in good agreement with reference values |
| 4 | Al-Khabori et al | Abbott Cell-Dyn Sapphire hematology analyzer | Masimo Pronto-7 Pulse | +0.2 g/dL | Correlation coefficient 0.46 with reference and 0.78 for two CO- oximetry Hb measurements | – | CO-oximetry method validated for blood donor Hb screening |
| 5 | Ardin et al | Sysmex KX-21N | NBM 200 | −0.12±1.14 g/dL | 91.7% | – | NIS method suitable for donor screening as they might preserve existing or encourage first-time donors and also retain former donors to donate blood |
| Pronto-7 | −0.50±0.99 g/dL | 86.4% | |||||
| HemoSpect | −0.22±1.24 g/dL | 88.4% | |||||
| 6 | Baart et al | Sysmex XT-188i | NBM 200 | Males: +0.10±0.60 mmol/L | 91.2 | Sensitivity 12.1%, specificity 98.6%, PPV 43.8% and NPV 92.4% | Measurements with invasive devices showed stronger correlation and better agreement with venous values than NIS |
| Females: +0.19±0.65 mmol/L | 82.6 | Sensitivity 17.0%, specificity 94.6%, PPV 36.4% and NPV 86.2% | |||||
| HemoSpect | Males: −0.06±0.73 mmol/L | 88.4% | Sensitivity 3.5%, specificity 95.9%, PPV 7.1% and NPV 91.8% | ||||
| Females: −0.06±0.64 mmol/L | 83.7% | Sensitivity 10.8%, specificity 95.0%, PPV 25% and NPV 87.4% | |||||
| 7 | Belardinelli et al | Beckman Coulter | NBM 200 | +0.29±0.98 g/dL | 88% | Sensitivity 98% and specificity 97% | Low correlation between NIS and laboratory Hb measurement |
| Pronto-7 | −0.53±1.04 g/dL | 78% | Sensitivity 93% and specificity 83% | ||||
| 8 | Sumnig et al | Siemens Advia 2120i | Pronto-7 | −5.9 g/L* | 74.75% | Sensitivity 63.2%, specificity 76.2%, PPV 24.8%, NPV 94.3% and CV 2.73% | NIS reasonable first-line approach for pre-donation Hb screening of blood donors |
| 9 | Singh et al | SysmexKX-21 | NBM 200 | −0.66 g/dL | ICC 0.43 | Sensitivity 71.1%, specificity 79.5%, PPV 30.2%, NPV 95.8% and CV 4.28% | NIS not effective in excluding ineligible donors, which may pose a threat to donors’ health |
Note: Data presented as mean ± standard deviation.
Abbreviations: ICC, intraclass correlation coefficient; NIS, noninvasive spectrophotometry; SD, standard deviation; Hb, hemoglobin; CV, coefficient of variation; PPV, positive predictive value; NPV, negative predictive value.